Treating cancer requires aggressive but targeted therapy. Some cancer drugs are too toxic because they damage healthy cells as well as tumor cells. So researchers are trying to develop ways to make sure drugs only target the right cells. One solution is to attach drugs to antibodies specific to a protein expressed on tumour cells. These drugs are called antibody-drug conjugates (ADCs).
More than two dozen ADCs are currently being used in the clinic to treat diseases like Hodgkin's lymphoma and breast cancer, and researchers are developing many more. But it's taken decades to find the right combination of drug, antibody target and linker, and then make sure the right amount of ADC hits the tumor.
In this 3D animation, produced by Nature Biotechnology, we hear about these challenges and the ways ADCs target cells.
This content is editorially independent of sponsors.
Animation by Nucleus Inc.. www.nucleuscatalog.com/home
Cancer treatment requires aggressive intervention, but some drugs such as monomethyl-oristatin
E are too toxic for systemic administration because they damage healthy cells as well
as tumour cells.
However, attaching the drug to an antibody targeting a surface protein highly expressed
on tumour cells can prevent collateral damage.
Different linkers can be used to attach a drug to an antibody.
These linkers are designed to break down and release active drug only after antibody-drug
conjugate enters the tumour cell.
This allows drugs to be activated only at the tumour site.
Unfortunately, certain factors can waylay the conjugate before it gets there.
First, the linker can break, releasing the drug from the antibody prematurely.
The free drug can then kill healthy normal cells, leading to a variety of side effects
including peripheral neuropathy.
To prevent this, efforts to engineer more stable linkers less likely to break are underway.
Second, healthy cells can ingest antibody-drug conjugate.
In most cases, conjugates are ultimately recycled back out of the cell without causing damage.
Conjugates that are not efficiently recycled can kill the cells in which they are retained.
A small percentage of the antibody-drug conjugates ultimately reach the tumour, but even conjugates
that reach the tumour may not kill tumour cells.
For example, if the cell doesn't internalise the conjugate, the drug can't kill the cell.
Efforts are underway to ensure that proteins selected as new conjugate targets get internalised
into the cell.
In successful therapy, tumour cells internalise sufficient numbers of conjugates.
Once inside the cell, conjugate linkers may be broken, for example by lysosomal enzymes.
Active drug then enters the cytoplasm, inflicting lethal damage.
One common mechanism to kill cells is to inhibit assembly of microtubules, which are essential
for cell division.
Tumour cells that cannot divide die by apoptosis.
Active drug released from dying tumour cells can kill nearby cells, including other tumour
cells and stromal cells.
Antibody-drug conjugates target the toxic effects of chemotherapeutic drugs to tumour
cells, thereby minimising the type of collateral damage that leads to unwanted side effects.